Researchers conducted a study to determine if variations in the MTNR1A gene, specifically the MRNR1A variant (rs374152717), could be a genetic cause of idiopathic osteoporosis.
"Angitia doses first subject in Phase II trial of AGA2118 for treating osteoporosis" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
Researchers employed analysis tools and machine learning algorithms to identify two genes linked to rheumatoid arthritis and osteoporosis that could serve as diagnostic tools and potential targets for ...
Osteoporosis occurs when your bones lose mineral ... Let’s explore the symptoms, causes, and treatment options for both conditions. Many people with Paget disease don’t have noticeable ...
Panelists discuss how to effectively integrate vasomotor symptom (VMS) treatment into comprehensive health management plans for women, taking into account the significant comorbidities associated with ...
There are alternatives', but doctors urge existing patients to stay on treatment The Royal Australian College of General Practitioners (RACGP) this year updated its guidance for osteoporosis ...